Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND Dysmetabolic profile has been associated with native aortic valve stenosis. However, there are limited data on the effects of an atherogenic milieu and its potential implications on the structural and hemodynamic deterioration of aortic bioprosthetic valves. OBJECTIVES This prospective longitudinal study sought to determine the predictors and impact on outcomes of hemodynamic valve deterioration (HVD) of surgically implanted aortic bioprostheses. METHODS A total of 137 patients with an aortic bioprosthesis implanted for a median time of 6.7 (interquartile range: 5.1 to 9.1) years prospectively underwent a first (baseline) assessment with complete Doppler echocardiography, quantitation of bioprosthesis leaflet calcification by multidetector computed tomography (CT), and a fasting blood sample to assess cardiometabolic risk profile. All patients underwent a second (follow-up) Doppler echocardiography examination at 3 (interquartile range: 2.9 to 3.3) years post-baseline visit. HVD was defined by an annualized change in mean transprosthetic gradient ≥3 mm Hg/year and/or worsening or transprosthetic regurgitation by ≥1/3 class. The primary endpoint was a nonhierarchical composite of death from any cause or aortic reintervention procedure (redo surgical valve replacement or transcatheter valve-in-valve implantation) for bioprosthesis failure. RESULTS Thirty-four patients (25.6%) had leaflet calcification on baseline CT, and 18 patients (13.1%) developed an HVD between baseline and follow-up echocardiography. Fifty-two patients (38.0%) met the primary endpoint during subsequent follow-up after the second echocardiographic examination. Leaflet calcification (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 1.35 to 4.82; p = 0.005) and HVD (HR: 5.12; 95% CI: 2.57 to 9.71; p < 0.001) were independent predictors of the primary endpoint. Leaflet calcification, insulin resistance (homeostatic model assessment index ≥2.7), lipoprotein-associated phospholipase A2 activity (Lp-PLA2 per 0.1 nmol/min/ml increase), and high level of proprotein convertase subtilisin/kexin 9 (PCSK9) (≥305 ng/ml) were associated with the development of HVD after adjusting for age, sex, and time interval since aortic valve replacement. CONCLUSIONS HVD identified by Doppler echocardiography is independently associated with a marked increase in the risk of valve reintervention or mortality in patients with a surgical aortic bioprosthesis. A dysmetabolic profile characterized by elevated plasma Lp-PLA2, PCSK9, and homeostatic model assessment index was associated with increased risk of HVD. The presence of leaflet calcification as detected by CT was a strong predictor of HVD, providing incremental risk-predictive capacity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
Brown, J. M., O'Brien, S. M., Wu, C., Sikora, J. A. H., Griffith, B. P., & Gammie, J. S. (2009) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.08.015 · Cited by 937 · cited 1×
“This temporal change is in large part related to: 1) the low thrombogenicity of bioprostheses and the fact that they do not require lifetime anticoagulation; 2) the improvement in valve hemodynamics, particularly in the small bioprosthetic sizes; and 3) the introduction of transcatheter AVR (4,5).”
BackgroundDarapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579
Ethnic differences in the ability of triglyceride levels to identify insulin resistance
Sumner, A. E., & Cowie, C. C. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.018 · Cited by 273 · cited 1×
“7, which represents the upper tertile of the study population as well as the previously reported threshold to detect insulin-resistance (25).”
BackgroundMerki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124
Cited by
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 1,982
Degeneration of Bioprosthetic Heart Valves: Update 2020
Kostyunin, A. E., Yuzhalin, A. E., Rezvova, M. A., Ovcharenko, E. A., Glushkova, T. V., & Kutikhin, A. G. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018506 · Cited by 347
2020 ACC/AHA guideline for the management of patients with valvular heart disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.002 · Cited by 279
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Perrot, N., Valerio, V., Moschetta, D., Boekholdt, S. M., Dina, C., Chen, H. Y., Abner, E., Martinsson, A., Manikpurage, H. D., Rigade, S., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.004 · Cited by 91
Self-citationWu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-15525-4 · Cited by 3
“Circulating PCSK9 levels have previously been linked with bioprosthetic aortic valve degeneration 35,36 .”
Biomarkers Associated with Aortic Stenosis and Structural Bioprosthesis Dysfunction
Oury, C., Côté, N., & Clavel, M.-A. (2020) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.005 · Cited by 2
Self-citation
Metadata
- Authors
- Salaun, E., Mahjoub, H., Dahou, A., Mathieu, P., Larose, É., Després, J.-P., Rodés-Cabau, J., Arsenault, B. J., Puri, R., Clavel, M.-A., & Pibarot, P.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 72
- Issue
- 3
- Pages
- 241-251
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2852705311
- Cited by
- 93
- References
- 6
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.